Talon Private Wealth LLC Purchases 1,630 Shares of United Therapeutics Corporation $UTHR

Talon Private Wealth LLC grew its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 31.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,753 shares of the biotechnology company’s stock after buying an additional 1,630 shares during the period. Talon Private Wealth LLC’s holdings in United Therapeutics were worth $3,659,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Toth Financial Advisory Corp boosted its holdings in United Therapeutics by 2,400.0% in the 2nd quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 48 shares during the period. WealthCollab LLC increased its holdings in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares during the period. Rakuten Securities Inc. raised its position in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 46 shares in the last quarter. Fiduciary Financial Advisors acquired a new stake in shares of United Therapeutics in the second quarter valued at approximately $30,000. Finally, Entrust Financial LLC bought a new stake in shares of United Therapeutics in the fourth quarter valued at approximately $31,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. Morgan Stanley set a $515.00 price target on United Therapeutics in a research report on Thursday, August 6th. Bank of America cut their target price on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Royal Bank Of Canada reduced their target price on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Finally, JPMorgan Chase & Co. upped their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $646.00.

Insider Activity at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 9,500 shares of the company’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $502.35, for a total transaction of $4,772,325.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares in the company, valued at approximately $162,983,941.05. This represents a 2.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $482.03, for a total value of $4,000,849.00. Following the completion of the transaction, the executive vice president owned 45,172 shares of the company’s stock, valued at $21,774,259.16. The trade was a 15.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 384,075 shares of company stock worth $202,367,758 over the last ninety days. 8.60% of the stock is currently owned by insiders.

United Therapeutics Stock Performance

Shares of United Therapeutics stock traded down $6.75 during trading on Friday, reaching $497.11. 359,358 shares of the company’s stock were exchanged, compared to its average volume of 494,315. United Therapeutics Corporation has a 1-year low of $396.12 and a 1-year high of $609.35. The company has a market cap of $21.32 billion, a P/E ratio of 17.79, a PEG ratio of 2.53 and a beta of 0.56. The firm’s 50-day moving average price is $522.08 and its 200 day moving average price is $540.60.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. The firm had revenue of $783.30 million for the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $6.41 earnings per share. As a group, equities research analysts predict that United Therapeutics Corporation will post 26.33 EPS for the current year.

United Therapeutics Profile

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics’ PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.